A Randomized Phase II Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where cisplatin-Based Treatment is Not an Option

Brief Summary

Type:
Urologic / Genitourinary - Other

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT03237780

Study #:
STUDY00143043

Start Date:
May 27, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03237780

View Complete Trial Details & Eligibility at ClinicalTrials.gov